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CYP2C19*2(GA) carries is a statistically non significant with basal aggregation, be-
fore PCI, day after PCI, and after PCI, while significant with inhibition percentage
before PCI.CONCLUSIONS: Therewas a variable individual response to Clopidogrel
between patients carries CYP2C19*1.CYP2C19*2 (GA) genotype and carries
CYP2C19*1.CYP2C19*1 (GG) genotype.
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OBJECTIVES: This study examined VTE prophylaxis and VTE risk reduction and
readmission in a cohort of hospitalized medically ill patients in the real-world
clinical setting during hospitalization and post discharge. METHODS: This 5-year
retrospective study used linked outpatient files from MarketScan® Commercial
and Medicare Supplemental databases, thereby providing continuity of therapy
through hospitalization and post-discharge. Patients were categorized into pro-
phylaxis and non-prophylaxis groups based on use of any guideline-recommended
anticoagulants from the index date to 180 days after index hospital discharge, and
before the date of the first VTE event. Outcome variables were VTE events and
re-hospitalization. Risk adjustment was conducted within the prophylaxis group,
and between the prophylaxis and non-prophylaxis groups using propensity score
matching. RESULTS: Among 3916 patients identified, 29.37% (n1295) were admit-
ted with cancer, 18.25% (n805) with pneumonia, 14.24% (n628) with heart fail-
ure, 11.25% (n496) with sepsis, 8.19% (n361) with infectious diseases, 5.67%
(n250) with severe respiratory disorders, and 1.84% (n81) with inflammatory
bowel disease (IBD). Among these patients, only 1819 (51.81%) received anticoagu-
lant therapy and 242 (6.18%) received non-pharmacological prophylaxis only dur-
ing their hospitalization and until 180 days after discharge. The anticoagulant
therapy rates ranged from 88.64% in obesity to 32.39% in IBD patients. Among
patients who received anticoagulant therapy, 740 (40.68%) received low molecular
weight heparin only and 806 (44.31%) received unfractionated heparin. After risk
adjustment, compared to patients without VTE prophylaxis, those patients who
received anticoagulant prophylaxis had lower VTE rates (3.62% vs. 4.27%., p0.04)
and lower readmission rates (24.22% vs 27.95%, p0.02) during the 6-month period
from the index hospital admission. CONCLUSIONS: Despite existing guidelines,
anticoagulant prophylaxis is underutilized inmedically ill patients in clinical prac-
tice. Anticoagulant prophylaxis is associated with reduced risk of VTE and rehos-
pitalization in medically ill patients.
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OBJECTIVES: The association of antihypertensive medication adherence with oc-
currence of complications and all-cause medical costs was examined using data
from the Health Insurance Review and Assessment Service(HIRA).METHODS: This
studywas a retrospective analysis of HIRA administrative claims data from January
2005 to December 2009. All subjects initiating therapy with oral antihypertensive
drugs were identified in January through December 2006. The index date was the
date of the first hypertension-related prescription. Patients were observed for 1
year before and 3 years after therapy initiation. Outcomes included occurrence of
complications and all-cause medical costs; occurrence of complications was mea-
sured starting 2 years after therapy initiation through follow-up and all-causemed-
ical costsweremeasured all durations of follow-up. Adherencewasmeasuredwith
a medication possession ratio (MPR) and categorized 19%, 20-39%, 40-59%, 60-
79%, and 80%. Using Cox survival regression, Occurrence of complications was
modeled at levels of MPR. All-cause medical costs were modeled with generalized
linear model regression. RESULTS: Average MPR in the total of 290,602 hyperten-
sion patients was 82.8%(21.2). In Cox survival analysis, risk of complications in-
creased as levels of MPR decreased. Patients with the lowest MPR level versus
optimal adherence had 3 times higher risk of complications (hazard ratio3.00,
95%CI2.69-3.35). Under the adjustmentwith covariates, annual all-causemedical
costs per patient were 23% higher for patients with the lowest MPR level versus
optimal level (exponential coefficient1.23, 95% CI1.20-1.25). The costs, however,
were 2-7% lower for groups with MPR 20-39%, 40-59% and 60-79%, because phar-
macy costs offset in/out-patient care cost saving. CONCLUSIONS: This study
showed strong associations between decreased antihypertensive medication ad-
herence and increased risk of complication occurrence. And the lowest adherence
was associated with higher all-cause medical costs. Further research is needed in
longer than 3 year follow-ups to assess the economic impact of adherence.
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OBJECTIVES: To compare baseline characteristics and dosage patterns among Jap-
anese patients newly started on statin. METHODS: Patients 18 years were iden-
tified between June 2006 to August 2010, with a minimum 6-month pre- and 12-
month post-index health plan eligibility from the Japan Medical Data Center
Database. A 90-day statin-free washout period was applied to identify patients in
whom statin therapywas newly prescribed. The index datewas defined as the date
of the first statin prescription. Five cohorts were created based on index statins
[atorvastatin (ATS), simvastatin (SIS), rosuvastatin (ROS), pitavastatin (PTA), and
pravastatin (PRS)] comparing demographics, comorbidities, statin dosage patterns,
prior medication, health care costs and resource utilization. RESULTS: There were
14,675 patients identified across 5 cohorts: 27.7% ATS, 6.4% SIS, 26.9% ROS, 12.9%
PTA and 26.0% PRS. PTA cohort had more diabetes (PTA 14.0% vs. ATS 10.2%, SIS
6.5%, ROS 12.8%, PRS 9.6%) and coronary artery diseases (PTA 8.6% vs. ATS 7.7%, SIS
4.1%, ROS 7.4%, PRS 7.3%). ROS cohort had more prior peripheral vascular disease
(ROS 6.6% vs. ATS 5.6%, SIS 3.6%, PTA 5.6%, PRS 5.5%), cerebrovascular disease (ROS
7.0% vs. ATS 6.6%, SIS 2.9%, PTA 5.7%, PRS 6.3%), and hypertension (ROS 33.2% vs.
ATS 30.2%, SIS 27.4%, PTA 30.9%, PRS 30.2%). SIS cohort hadmore prior outpatients
visits (SIS 9.6 vs. ATS 8.2, ROS 8.7, PTA 8.2, PRS 9.3). Prior healthcare costs were
similar across 5 cohorts. Majority of patients were prescribed lower statin doses:
ATS, 10mg (60%); SIS, 5mg (86%); ROS, 2.5mg (89%); PTA, 1mg (49%); PRS, 10mg
(62%).CONCLUSIONS: Japanese patients newly started on a statin had similar prior
health care costs, andwere prescribed lower doses compared toWestern countries.
Patients with diabetes and coronary artery diseases were more likely to be pre-
scribed PTA.
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OBJECTIVES: To describe demographics, treatment patterns and outcomes of pa-
tients with pulmonary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) treated under everyday practice.METHODS: Ret-
rospective chart review of PAH (N285) and CTEPH (N120) patients treated with
endothelin receptor antagonists, prostacyclin analogues or PDE-5 inhibitors be-
tween July 2003 and June 2009 in specialized centers in 6 countries (France, Ger-
many, Italy, Spain, Sweden, and United Kingdom). Data were extracted from pa-
tient files and analyzed descriptively. For survival analysis, Kaplan-Meier
estimates were used. RESULTS: PAH patients (idiopathic 49.8%, mean age
55.315.6 years, 74.4% females, 6-min-walk-distance [6-MWD] 328121 meters,
NYHA class II/III/IV in 20/66/14%) and CTEPH patients (83.7% inoperable and 15.8%
persistent after surgery, 67.512.1 years, 60.0% females, 6-MWD 298120 meters,
NYHA II/III/IV in 27/58/15%). Mean pulmonary arterial pressure was 5016 mmHg
in PAH and 4511 mmHg in CTEPH. Mean pulmonary vascular resistance was
939760 dyn*s*cm-5 in PAH and 797726dyn*s*cm-5 in CTEPH. At baseline, 93.7%
PAH patients received monotherapy (bosentan 47.0%, sildenafil 35.8%), with con-
comitant diuretics (40.0%) and anticoagulants (30.2%). CTEPH patients received
monotherapy in 99.2% (bosentan 56.7%, sildenafil 34.8%), with concomitant diuret-
ics (59.2%) and anticoagulants (62.5%). Mean observation time was 2.2 years (PAH)
and 2.1 years (CTEPH). At end of observation, in the PAH group mean 6-MWD
increased by 3291 meters and by 3090 in the CTEPH group. In the PAH group,
29.1% of patients improved, 63.8%were unchanged, 7.1% deteriorated in the NYHA
class, and 20.4% died (annualized death rate 10.3%); in the CTEPH group 32.2%
improved, 59.3% were unchanged, 8.5% deteriorated, and 13.3% died (annualized
death rate 6.4%). CONCLUSIONS: These data reflect real-life treatment patterns in
PAH and CTEPH patients in a period when several new PAH-specific treatments
were introduced. Overall, drug utilization was similar in PAH and CTEPH patients
(although off-label in the latter group). In viewof outcomes there still a great unmet
need, especially for patients with CTEPH.
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OBJECTIVES: The aims of this contribution are to update andmore precisely quan-
tify the age and gender-specific prevalence and incidence of atrial fibrillation (AF)
in an European setting (Germany).METHODS:To fulfill the aims of the study, it was
decided to make a population-based analysis of the claims data collected by a
statutory health insurance fund, and concerning its 8.298 million members. A pa-
tient was classified as AF prevalent if he/she had received at least two outpatient
diagnoses of AF (ICD10-Code I48.1) in two different quarters of the year and/or had
received at least one main AF diagnosis during inpatient treatment between Janu-
ary 1, 2007 andDecember 31, 2008. A patientwas considered to have had new onset
AF in 2008 under one of three conditions; firstly, he/she had not received a diagno-
sis of AF in 2007; secondly, had not received oral anticoagulant medication in 2007;
and thirdly, had received either one inpatient AF diagnosis in 2008, or two such
outpatient diagnosis made in different quarters of that year. AF prevalence is re-
ported in %, AF incidence is reported as cases per 1000 person-years. RESULTS: In
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